In the latest trading session, 0.46 million CureVac N.V (NASDAQ:CVAC) shares changed hands as the company’s beta touched 2.46. With the company’s most recent per share price at $4.14 changing hands around $0.2 or 5.20% at last look, the market valuation stands at $929.74M. CVAC’s current price is a discount, trading about -27.54% off its 52-week high of $5.28. The share price had its 52-week low at $2.21, which suggests the last value was 46.62% up since then. When we look at CureVac N.V’s average trading volume, we note the 10-day average is 1.72 million shares, with the 3-month average coming to 713.58K.
Analysts gave the CureVac N.V (CVAC) stock a consensus recommendation rating of Buy, calculated at a mean rating of 2.17. If we narrow down to specifics, the data shows that 0 out of 2 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended CVAC as a Hold, 2 felt it is a Buy and 0 rated the stock as Underweight. CureVac N.V’s EPS for the current quarter is expected to be -0.12.
CureVac N.V (NASDAQ:CVAC) trade information
Instantly CVAC is in green as seen in intraday trades today. With action -6.64%, the performance over the past five days has been red. The company’s shares are showing year-to-date upside of 21.55%, with the 5-day performance at -6.64% in the red. However, in the 30-day time frame, CureVac N.V (NASDAQ:CVAC) is 26.95% up. Looking at the short shares, we see there were 3.82 million shares sold at short interest cover period of 6.54 days.
The consensus price target for the stock as assigned by Wall Street analysts is 29, meaning bulls need an upside of 85.72% from its recent market value. According to analyst projections, CVAC’s forecast low is 21 with 37 as the target high. To hit the forecast high, the stock’s price needs a -793.72% plunge from its current level, while the stock would need to soar -407.25% for it to hit the projected low.
CureVac N.V (CVAC) estimates and forecasts
Data shows that the CureVac N.V share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot 15.14% over the past 6 months, a 156.25% in annual growth rate that is considerably higher than the industry average of 16.70%. Year-over-year growth is forecast to reach 885.84% up from the last financial year.
Consensus estimates given by 4 financial analysts project the company’s revenue in the current quarter to hit an average of 6.5M. 2 analysts are of the opinion that CureVac N.V’s revenue for the current quarter will be 13.56M. The company’s revenue for the corresponding quarters a year ago was 22.6M and 12.37M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -71.24%. The estimates for the next quarter sales put growth at 9.57%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -23.15%. The 2025 estimates are for CureVac N.V earnings to increase by 169.42%.
CureVac N.V (NASDAQ:CVAC)’s Major holders
POINT72 ASSET MANAGEMENT, L.P. holds the second largest percentage of outstanding shares, with 1.0802% or 2.42 million shares worth $8.24 million as of 2024-06-30.
Among Mutual Funds, the top two as of Oct 31, 2024 were iShares Biotechnology ETF and iShares Core MSCI EAFE ETF. With 651.42 shares estimated at $2.71 million under it, the former controlled 0.29% of total outstanding shares. On the other hand, iShares Core MSCI EAFE ETF held about 0.26% of the shares, roughly 582.29 shares worth around $2.42 million.
